Incyte Corporation $INCY Stock: Danske Bank A S Boosts Position

Danske Bank A S lifted its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 84.4% in the 3rd quarter, Holdings Channel reports. The firm owned 150,974 shares of the biopharmaceutical company’s stock after purchasing an additional 69,112 shares during the quarter. Danske Bank A S’s holdings in Incyte were worth $18,321,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fiduciary Financial Advisors acquired a new stake in Incyte in the second quarter valued at $26,000. Provenance Wealth Advisors LLC acquired a new position in Incyte in the 3rd quarter valued at $33,000. Continuum Advisory LLC purchased a new position in Incyte during the second quarter worth about $36,000. Latitude Advisors LLC purchased a new stake in shares of Incyte during the 3rd quarter valued at $39,000. Finally, Quantbot Technologies LP acquired a new stake in Incyte during the second quarter worth about $52,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte News Summary

These are some of the INCY news items that stood out recently:

  • Positive Sentiment: The European Commission approved Povofortay as the first once-daily oral treatment for moderate-to-severe HS in Europe. The decision gives Incyte a new commercial opportunity in a chronic skin condition and a differentiated oral option for patients. The approval could support future growth, although the news does not specify launch timing or expected sales. Company announcement
  • Neutral Sentiment: EVP Lee Heeson sold 10,694 shares for about $1.29 million, reducing his holdings by 28.46%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it less clearly a signal about the executive’s view of the company. Insider sale report

Incyte Stock Down 1.0%

Shares of NASDAQ:INCY opened at $119.09 on Wednesday. The company’s fifty day moving average is $118.94 and its two-hundred day moving average is $109.14. Incyte Corporation has a 12-month low of $89.25 and a 12-month high of $132.60. The company has a market cap of $24.27 billion, a P/E ratio of 56.73, a price-to-earnings-growth ratio of 4.38 and a beta of 0.78.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.93) by $0.33. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. Incyte’s quarterly revenue was up 14.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.26 earnings per share. Equities research analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, CMO Steven H. Stein sold 240,193 shares of the stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $118.39, for a total value of $28,436,449.27. Following the completion of the sale, the chief marketing officer directly owned 30,916 shares of the company’s stock, valued at $3,660,145.24. This represents a 88.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Heeson sold 10,694 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $120.82, for a total transaction of $1,292,049.08. Following the sale, the executive vice president owned 26,884 shares of the company’s stock, valued at approximately $3,248,124.88. This represents a 28.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 254,139 shares of company stock worth $30,098,844. Insiders own 16.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on INCY shares. Piper Sandler lifted their target price on shares of Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Mizuho lifted their price objective on Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Morgan Stanley assumed coverage on shares of Incyte in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 price target on the stock. Zacks Research raised shares of Incyte from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 12th. Finally, UBS Group set a $152.00 price target on Incyte in a report on Friday, October 30th. Eleven equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $133.86.

Read Our Latest Analysis on Incyte

Incyte Company Profile

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Featured Articles

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.